Narazaciclib refers to a category of multi-targeted kinase inhibitors that function as antineoplastic agents by selectively inhibiting Cyclin-Dependent Kinases 4 and 6, as well as the NUAK family SNF1-like… Read more
Narazaciclib refers to a category of multi-targeted kinase inhibitors that function as antineoplastic agents by selectively inhibiting Cyclin-Dependent Kinases 4 and 6, as well as the NUAK family SNF1-like kinase 1. This compound is currently under investigation for its potential to treat solid tumors and multiple myeloma by disrupting cell cycle regulation and inhibiting cancer cell proliferation. This product category supports rigorous analytical testing by providing high-quality reference standards, including the parent compound, its desmethyl metabolite, and N-oxide derivatives. Furthermore, stable isotope labelled compounds such as deuterated analogues are essential for precise impurity profiling and method validation. Laboratories rely on these materials for accurate quantification and to assess metabolic stability during quality control procedures, ensuring that analytical methods meet strict regulatory compliance for pharmaceutical research and development.